Ranbaxy gains on settlement buzz ahead of generic Lipitor launch plans
This article was originally published in Scrip
Executive Summary
Shares of Ranbaxy Laboratories moved up on Indian bourses following reports that the company may be edging towards a settlement with US regulators, days ahead of the potential launch of a generic version of Pfizer's cholesterol drug, Lipitor (atorvastatin) in the US by the month-end.